Advertisement for orthosearch.org.uk
Results 1 - 2 of 2
Results per page:
Applied filters
General Orthopaedics

Include Proceedings
Dates
Year From

Year To
Orthopaedic Proceedings
Vol. 100-B, Issue SUPP_5 | Pages 7 - 7
1 Apr 2018
Habashy A Casale M Waddell B Chimento G Sherman W
Full Access

Introduction

Body Mass Index (BMI) is an essential tool for orthopaedic surgeons in regards to preoperative risk stratification as well as assessment of overall health and nutritional status. Patient's self-awareness of their height, weight and BMI is crucial in maintaining a healthy lifestyle. The purpose of our study was to determine the accuracy of orthopaedic patient's reported height and weight. We hypothesized that a patient's age, sex and/or BMI may affect the accuracy of these reported values.

Methods

After IRB approval, we performed a prospective, observational study in the setting of our orthopaedic clinic. Patients were asked to report their predicted height and weight and then were weighed and measured using a single standardized scale. All values, including age and sex, were recorded. Differences were then calculated. Patients were categorized based on their age (younger than 65 vs older than 65), sex, and actual BMI (less than 30 vs greater than 30). Student t-test was used to calculate significance (p <0.05 conferred significance).


Orthopaedic Proceedings
Vol. 99-B, Issue SUPP_4 | Pages 5 - 5
1 Feb 2017
Habashy A Sumarriva G Chimento G
Full Access

Background

Intravenous and topical tranexamic acid (TXA) has become increasingly popular in total joint arthroplasty to decrease perioperative blood loss. In direct comparison, the outcomes and risks of either modality have been found to be equivalent. In addition, current literature has also demonstrated that topical TXA is safe and effective in the healthy population. To our knowledge, there is a scarcity of studies demonstrating the safety of topical TXA in high risk patient populations undergoing total joint arthroplasty or revision joint arthroplasty. The purpose of this study is to determine the safety of topical TXA in patients undergoing total or revision arthroplasty that are also on chronic anticoagulant or anti-platelet therapy.

Methods

We performeded a retrospective review of patients undergoing primary and revision total hip or knee arthroplasties that received topical TXA (3g/100mL NS) from November 2012 to March 2015. All patients, regardless of co-morbidities, were included in the study population. Patients were divided into 3 groups:

Group 1: Patients without any antiplatelet or anticoagulant therapy within 90 days of surgery

Group 2: Patients receiving antiplatelet therapy (Aspirin and/or Plavix) within 90 days of surgery

Group 3: Patients receiving anti-coagulant therapy within 90 days of surgery (low molecular weight heparin, unfractionated heparin, warfarin, dabigatran, rivaroxaban, apixaban).

Chart review analyzing ICD-9 and ICD-10 coding was then utilized to establish any peri-operative complications within the 30 day post-operative period in all groups. Complications amongst the groups were evaluated via chi-squared testing as well as multivariate linear regression. Review of current literature and CMS protocols were used to establish reportable peri-operative complications. Wound infections, thromboembolic events and vascular complications such as myocardial infarction, pulmonary embolism, deep venous thrombosis, stroke, aortic dissection were included.